Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia

The covalent inhibitor of Bruton’s tyrosine kinase ibrutinib and the specific Bcl-2 inhibitor venetoclax are both highly efficacious single-agent drugs in the treatment of chronic lymphocytic leukemia (CLL). Based on their complementary modes of action, ibrutinib and venetoclax are hypothesized to a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kater, Arnon P., Slinger, Erik, Cretenet, Gaspard, Martens, Anne W., Balasubramanian, Sriram, Leverson, Joel D., Eldering, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
Stimulus Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153000/
https://www.ncbi.nlm.nih.gov/pubmed/34555843
http://dx.doi.org/10.1182/bloodadvances.2021004861

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153000/
https://www.ncbi.nlm.nih.gov/pubmed/34555843
http://dx.doi.org/10.1182/bloodadvances.2021004861

Ejemplares similares